News
ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to ...
Charles Boynton; Chief Financial Officer; Nextracker Inc. Daniel Shugar; Chief Executive Officer, Director; Nextracker Inc. Howard Wenger; President, Director; Nextr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback